Listen to this article

Dr. Reddy’s Laboratories Ltd. has acquired MenoLabs, a women’s health and dietary supplement portfolio from California-based Amyris Inc. 

The deal follows Amyris’ August 2023 Chapter 11 bankruptcy filing, when the biotech announced it planned to sell its consumer brands, according to a Reuters report. Amyris acquired MenoLabs just two years ago, in January 2022.

Dr. Reddy’s – which is headquartered in India and has its U.S. base in Princeton – told NJBIZ  Jan. 4 it was not disclosing financial terms of the deal at this time. 

The acquisition includes the entire MenoLabs supplements portfolio: seven branded products designed to address symptoms of perimenopause and menopause. Those brands are MenoFit and MenoGlow probiotics; Happy Fiber and Well Rested dietary supplements; Athena’s Shield menopause support supplement; and Goodness Glow and Keep Glowing Gorgeous supplements for healthy aging support.  

Dr. Reddy’s also obtained Amyris’ MenoLife health tracker app, which supports the product line and provides information on menopause.  

MenoLabs products are sold in the U.S., primarily through menolabs.com and other e-commerce marketplaces such as Amazon and Walmart. 

Marc Kikuchi, CEO for Dr. Reddy’s in North America, said the deal “complements Dr. Reddy’s U.S. self-care and wellness business portfolio of brands and addresses unmet needs of consumers for science-based, research-driven products that provide relief from the symptoms of menopause.” 

In February 2023, Dr. Reddy’s made a move to strengthen its U.S. retail prescription business when it entered a definitive agreement to acquire a product portfolio of Mayne Pharma Group Ltd. for an upfront payment of approximately $90 million in cash, contingent payments of up to $15 million, along with other considerations.